Edition:
United States

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Aug 15 2018

Long-acting injection a shot in the arm for GSK's HIV business

LONDON A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business.

Aug 07 2018

Biotech entrepreneur Drayson plans to list new AI drug research firm

LONDON British biotech entrepreneur Paul Drayson plans to raise 60 million pounds ($78 million) through an initial public offering of a new company focused on artificial intelligence in healthcare.

Aug 03 2018

Cashing in on DNA: race on to unlock value in genetic data

LONDON How much is your DNA worth? As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.

Aug 01 2018

EU drugs agency sees 30 percent staff losses, more cuts in Brexit move

The European Medicines Agency (EMA) is to scale back operations further as it copes with higher than expected staff losses, triggered by the watchdog's forced relocation from London to Amsterdam because of Brexit.

Jul 26 2018

New drugs shine as AstraZeneca treads path back to growth

LONDON AstraZeneca's new drugs performed strongly in the second quarter, offering a glimpse of better times ahead as the company struggles with falling sales of cholesterol fighter Crestor due to generic competition.

Jul 25 2018

GSK bets $300 million on genetics as CEO plays down break-up talk

LONDON GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a source of cash generation for such R&D investment.

Jul 24 2018

GSK's two-drug HIV treatment proves itself in key tests

LONDON GlaxoSmithKline's simple two-drug treatment for HIV works as well as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, clinical study results presented on Tuesday showed.

Jul 20 2018

EU drug regulators step up work to prepare for 'no deal' Brexit

LONDON Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit.

Jul 20 2018

Battle lines drawn as EU court weighs fate of gene-edited crops

LONDON Gene editing in agriculture takes centre stage next Wednesday when Europe's highest court rules in a case that could determine the fate of the technology that is already making waves in the field of medicine.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary